Phaseline

Targets › KIR3DL2

KIR3DL2 (Killer cell immunoglobulin-like receptor 3DL2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Apr 2028.

Receptor on natural killer (NK) cells and T cells for MHC class I molecules. Upon binding of peptide-free HLA-F open conformer, negatively regulates NK and T cell effector functions. (UniProt, P43630)

Open in Phaseline: the race on KIR3DL2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The Lymphoma Academic Research OrganisationLacutamab
anti-KIR3DL2 monoclonal antibody
KIR3DL2Phase 2Peripheral T Cell LymphomaApr 2028

Conditions

Peripheral T Cell Lymphoma (1)

Modalities

mixed (1)

Companies

The Lymphoma Academic Research Organisation (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.